Fungal coinfection/superinfection in COVID-19 patients in a tertiary hospital in Mexico

Autor:	García-Salazar E; Hospital Regional de Alta Especialidad Ixtapaluca, IMSS-BIENESTAR, Ciudad de México, México., Benavidez-López S; Hospital Regional de Alta Especialidad Ixtapaluca, IMSS-BIENESTAR, Ciudad de México, México., Bonifaz A; Laboratorio de Micología, Servicio de Dermatología, Hospital General de México 'Dr. Eduardo Liceaga', Ciudad de México, México., Hernández-Mendoza EA; Hospital Regional de Alta Especialidad Ixtapaluca, IMSS-BIENESTAR, Ciudad de México, México., Ramírez-Magaña X; Hospital Regional de Alta Especialidad Ixtapaluca, IMSS-BIENESTAR, Ciudad de México, México., Reyes-Montes MDR; Laboratorio de Micología, Servicio de Dermatología, Hospital General de México 'Dr. Eduardo Liceaga', Ciudad de México, México; Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México., Duarte-Escalante E; Laboratorio de Micología, Servicio de Dermatología, Hospital General de México 'Dr. Eduardo Liceaga', Ciudad de México, México; Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México., Acosta-Altamirano G; Hospital Regional de Alta Especialidad Ixtapaluca, IMSS-BIENESTAR, Ciudad de México, México., Frías-De-León MG; Hospital Regional de Alta Especialidad Ixtapaluca, IMSS-BIENESTAR, Ciudad de México, México.
Jazyk:	English; Spanish; Castilian
Zdroj:	Biomedica : revista del Instituto Nacional de Salud [Biomedica] 2024 Aug 29; Vol. 44 (3), pp. 328-339. Date of Electronic Publication: 2024 Aug 29.
DOI:	10.7705/biomedica.7251
Abstrakt:	Introduction: Data on the prevalence of fungal coinfections/superinfections in patients with COVID-19 are limited. Objective: To describe the prevalence of fungal coinfections/superinfections in patients with COVID-19, as well as risk factors and demographic, clinical, and microbiological characteristics. Material and Methods: We included patients with a confirmed COVID-19 diagnosis and a confirmed fungal infection hospitalized in the ICU from March 2020 to December 2021. We collected data on age, sex, comorbidities, hospital length of stay (days), laboratory (ferritin) and microbiological results, treatment for COVID-19, antifungal therapy, and outcomes obtained from the clinical records. Results: Only 11 out of 740 patients met the inclusion criteria. The coinfection rate was 0.3% and the superinfection was 1.2%. The most affected population was male adults. The coinfections/superinfections diagnosed were candiduria and candidemia, caused by Candida albicans, C. tropicalis, C. glabrata, C. lusitaniae, and Kluyveromyces marxianus (C. kefyr). In addition, tracheobronchitis due to Aspergillus fumigatus was found. The most used antifungals were fluconazole and caspofungin. The lethality in patients with fungal coinfections was 50% and superinfections, 22%. The length of hospital stay was 11-65 days. Eight patients required mechanical ventilation and six received corticosteroids. The main comorbidity was diabetes mellitus (81.8%). Conclusions: The rate of fungal coinfections/superinfections in COVID-19 patients was low, but the lethality found urges for routine fungal screening in patients with severe COVID-19 to timely detect fungal infections that may further compromise the patient’s life.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu